The Economics of Human Lifespan and Healthspan Extension: Emerging Business Models in Preventive Care and Longevity Industry
In the U.S. and other developed countries, affluent individuals are spending substantial funds to achieve longer, healthier lives through preventive health services. The current preventive medicine industry is focusing on preventing age-related decline and the promise of extended health and vitality. Many companies, including longevity clinics, now prioritize healthspan as well as lifespan. Advances in biotechnology, artificial intelligence, genetics, and preventive medicine are creating new business opportunities across healthcare, technology, finance, and consumer wellness (World Economic Forum, 2024).
Advanced diagnostics and health monitoring represent a rapidly growing business segment. Companies such as Function Health, Viome, and Inside Tracker provide genetic testing, biological age assessments, blood biomarker analysis, microbiome testing, and full-body imaging to identify health risks before symptoms appear (Function Health, 2026). These firms often use subscription-based models, generating recurring revenue and promoting ongoing consumer engagement in health management.
In the U.S. and other developed countries, affluent individuals are spending substantial funds to achieve longer, healthier lives through preventive health services. The current preventive medicine industry is focusing on preventing age-related decline and the promise of extended health and vitality. Many companies, including longevity clinics, now prioritize healthspan as well as lifespan. Advances in biotechnology, artificial intelligence, genetics, and preventive medicine are creating new business opportunities across healthcare, technology, finance, and consumer wellness (World Economic Forum, 2024).
Longevity clinics and personalized health programs are also central to the industry. Clinics such as Next Health, Synergy Life Centers, and Fountain Life offer individualized plans that may include nutrition coaching, exercise optimization, sleep tracking, hormone therapies, preventive screenings, and ongoing physician oversight (Fountain Life, n.d.). Clients pay membership fees for continuous health management instead of annual checkups, providing a stable and scalable revenue stream (Patient Options, n.d.).
Biotechnology companies such as Altos Labs, Retro Biosciences, and Insilico Medicine are developing therapies to slow biological aging, reduce age-related diseases, improve cellular repair, and extend healthy lifespan. Many treatments remain experimental and lack FDA approval, yet successful therapies could create new preventive medicine markets worth billions of dollars. Large companies like Eli Lilly and Novo Nordisk signal significant opportunities for other companies (Clarivate, 2026). As the U.S. population ages, demand for interventions that preserve health and independence is expected to increase significantly.
Artificial intelligence is becoming a key tool in the longevity sector. AI platforms like Gero analyze large datasets from wearables, medical records, and diagnostic tests to identify health risks and recommend personalized interventions (Pyrkov et al., 2021). Companies generate revenue through software subscriptions, partnerships with healthcare providers, and direct-to-consumer digital health services.
Rising life expectancies are likely to create new opportunities in financial services. If more Americans routinely live into their nineties or beyond, traditional retirement models will need to be redesigned (OECD, 2023; Stanford Center on Longevity, 2021). Financial institutions may introduce new investment products, such as longevity funds, retirement planning services tailored to longer lifespans, and insurance solutions like longevity insurance. The high cost of treatments and services need to be reduced to remove health inequalities and enable industry growth (World Economic Forum, 2024).
If longevity treatments become widely accessible, increasing human lifespan could become a valuable asset in the U.S. economy, creating thousands of new companies supporting lifespan and healthspan extension in the second half of the twenty-first century (Scott et al., 2021).
References
Clarivate. (2026). Why longevity might be biopharma’s next big thing. Clarivate Life Sciences & Healthcare Blog. https://clarivate.com/life-sciences-healthcare/blog/why-longevity-might-be-biopharmas-next-big-thing/
Fountain Life. (n.d.). Best longevity clinics in the US. Fountain Life Blog. https://www.fountainlife.com/blog/best-longevity-clinics-in-the-us
Function Health. (2026). Our Mission: Give Everyone the Power to Live the 100-Year Life. Function Health. https://www.functionhealth.com/
OECD. (2023). Pensions at a Glance 2023: OECD Indicators. OECD Publishing. https://www.oecd.org/en/publications/pensions-at-a-glance-2023_678055dd-en.html
Patient Options. (n.d.). Membership medicine revenue models. Patient Options. https://patientoptions.org/membership-medicine-revenue-models/
Pyrkov, T. V., Sokolov, I. S., & Fedichev, P. O. (2021). Deep longitudinal phenotyping of wearable sensor data reveals independent markers of longevity, stress, and resilience. Aging, 13(6), 7900–7913. https://doi.org/10.18632/aging.202816
Scott, A. J., Ellison, M., & Sinclair, D. A. (2021). The economic value of targeting aging. Nature Aging, 1(7), 616-623. https://doi.org/10.1038/s43587-021-00080-0
Stanford Center on Longevity. (2021). The New Map of Life: 100-Year Lives. Stanford University. https://longevity.stanford.edu/the-new-map-of-life-report/
World Economic Forum. (2024). Longevity Economy Principles: The Foundation for a Financially Resilient Future (Insight Report). World Economic Forum in collaboration with Mercer. https://www3.weforum.org/docs/WEF_Longevity_Economy_Principles_2024.pdf
